Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexagon for ocular chemical injury
ACTRN12609000320257Phase 2Not yet recruiting
- Sponsor
- The University of Auckland
- Start
- May 2009
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chemical Eye Injury comparing Open-label safety run-in Nexagon, Randomized Nexagon plus standard of care and Randomized vehicle placebo plus standard of care (3 arms). Primary endpoint: Percentage reduction in corneal epithelial defect from baseline to Day 5. Planned start May 2009; status: not yet recruiting.
02
Drugs
lufepirsen
03
Conditions
Chemical Eye Injury
Beyond the preview
Go deeper on ACTRN12609000320257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000320257.